Review of Urgent Reversal Therapies for Oral Anticoagulation

Author(s)

Mondin, J.J., Short, M.R., King, G.S., Ratliff, P.D.

Author's Affiliation

Abstract

Anticoagulation has proven to be one of the most essential breakthroughs in cardiology in the last 100 years.  The first major oral anticoagulant, warfarin, is a 4-hydroxycourmarin first synthesized in the 1940s for use as a rodenticide.  It was not until 1954 that warfarin was finally approved by the FDA for use in patients requiring systemic anticoagulation.  For over 55 years, warfarin was the only oral anticoagulant available in the United States until the approval of dabigatran in 2010, ushering in the era of the direct oral anticoagulants. This article will review modalities of anticoagulation reversal including activated charcoal, hemodialysis, blood-derived products, and medications currently available as well as in development.

Keywords

Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, Reversal, Idarucizumab, Andexanet Alfa, Ciraparantag

Cite This Article

Mondin, J.J., Short, M.R., King, G.S., Ratliff, P.D. (2016). Review of Urgent Reversal Therapies for Oral Anticoagulation, International Journal for Pharmaceutical Research Scholars (IJPRS), 5(2), 343-350.